Bevacizumab Combined with Pemetrexed for Advanced Non-Squamous Non-Small Cell Lung Cancer

Share this content:

the Cancer Therapy Advisor take:

After being combined with standard first-line chemotherapy, bevacizumab (a monoclonal antibody against vascular endothelial growth factor) was shown to have clinical benefit for patients with advanced non-squamous non-small cell lung cancer.

Research recently published in Tumour Biology: The Journal of The International Society for Oncodevelopmental Biology and Medicine investigated the affect of combining bevacizumab with pemetrexed as it related to progression-free survival in patients with advanced non-squamous non-small cell lung cancer after the failure of a minimum of one prior chemotherapy treatment.

In order to be eligible for inclusion in the study, patients must have failed at least one prior platinum-based chemotherapy treatment, have metastatic, locally advanced, or recurrent non-squamous non-small cell lung cancer, and performance status of 0 to 2.

Patient in the study received 500 mg/mof intravenous pemetrexed on day 1 and folic acid, vitamin B12, dexamethasone, and 7.5 mg/kg of intravenous bevacizumab on day 1 of a 21-day cycle.

Treatment was administered until toxicity was unacceptable, disease progression occurred, or the treatment was stopped by request of the patient. The primary endpoint of the study was progression-free survival. Thirty-three patients were enrolled between December 2011 and October 2013.

The median age of enrolled patients was 55 years and 63.6% of patients were women. Median overall survival was 15.83 months (95 % confidence interval: 10.52, 21.15 months) and overall response rates were 6.45%. 

Overall, the research showed that combining bevacizumab and pemetrexed on a 21-day cycle is effective for improving the progression-free survival of patients with non-squamous non-small cell lung cancer who have failed prior therapies.

AbbVie Initiates Veliparib Trial for NSCLC
Bevacizumab was shown to have clinical benefit for patients with advanced non-squamous non-small cell lung cancer.
This study aims to investigate whether the addition of Bev to pemetrexed improves progression-free survival (PFS) in advanced ns-NSCLC patients after the failure of at least one prior chemotherapy regimens. The results may provide more a regimen containing Bev and pemetrexed for Chinese clinical practice in previously treated ns-NSCLC.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs